However, clinical outcomes for ALL and AML patients harboring a chromosomal translocation involving the lysine methyl transferase 2A (KMT2A) gene remain unsatisfactory, with a high risk of treatment failure and event-free survival rates of only 20–40% when treated with standard combination chemotherapy [4,5,6,7] in AML depending on the KMT2A translocation [5]. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.